VCT 220
Alternative Names: CX-11; VCT-220Latest Information Update: 24 Sep 2025
At a glance
- Originator Vincentage Pharma
- Developer Corxel Pharmaceuticals; Vincentage Pharma
- Class Antihyperglycaemics; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Obesity
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 25 Jul 2025 Vincentage Pharma completes a phase I pharmacokinetics trial (In volunteers) in China (PO, Tablet) (NCT06938529)
- 09 Jul 2025 Vincentage Pharma plans a phase I pharmacokinetics trial (In volunteers) in China (PO), in July 2025 (NCT07056842)
- 01 Jul 2025 Vincentage Pharma initiates pharmacokinetics phase I trial for Obesity (In volunteers) in China (PO, Tablet) (NCT07065058)